Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug:166:111-117.
doi: 10.1016/j.urology.2022.04.031. Epub 2022 May 8.

Comparison of Empiric Preventative Pharmacologic Therapies on Stone Recurrence Among Patients with Kidney Stone Disease

Ryan S Hsi  1 , Phyllis L Yan  2 , Joseph J Crivelli  3 , David S Goldfarb  4 , Vahakn Shahinian  5 , John M Hollingsworth  6
Affiliations

Comparison of Empiric Preventative Pharmacologic Therapies on Stone Recurrence Among Patients with Kidney Stone Disease

Ryan S Hsi et al. Urology. 2022 Aug.

Abstract

Objective: To compare the frequency of stone-related events among patients receiving thiazides, alkali citrate, and allopurinol without prior 24 h urine testing. It is unknown whether 1 preventative pharmacological therapy (PPT) medication class is more beneficial for reducing kidney stone recurrence when prescribed empirically.

Materials and methods: Using medical claims data from working-age adults with kidney stone disease diagnoses (2008-2018), we identified those prescribed thiazides, alkali citrate, or allopurinol. We excluded those who received 24 h urine testing prior to initiating PPT and those with less than 3 years of follow-up. We fit multivariable regression models to estimate the association between the occurrence of a stone-related event (emergency department visit, hospitalization, or surgery for stones) and PPT medication class.

Results: Our cohort consisted of 1834 (60%), 654 (21%), and 558 (18%) patients empirically prescribed thiazides, alkali citrate, or allopurinol, respectively. After controlling for patient factors including medication adherence and concomitant conditions that increase recurrence risk, the adjusted rate of any stone event was lowest for the thiazide group (14.8%) compared to alkali citrate (20.4%) or allopurinol (20.4%) (each P < .001). Thiazides, compared to allopurinol, were associated with 32% lower odds of a subsequent stone event by 3 years (OR 0.68, 95% CI 0.53-0.88). No such association was observed when comparing alkali citrate to allopurinol (OR 1.00, 95% CI 0.75-1.34).

Conclusion: Empiric PPT with thiazides is associated with significantly lower odds of subsequent stone-related events. When 24 h urine testing is unavailable, thiazides may be preferred over alkali citrate or allopurinol for empiric PPT.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Flowchart for cohort selection
Figure 1.
Figure 1.
Flowchart for cohort selection
Figure 2.
Figure 2.
Unadjusted and adjusted rates of symptomatic stone recurrence over 3 years comparing empiric preventive pharmacologic monotherapies.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

  • Thiazide Use for the Prevention of Recurrent Calcium Kidney Stones.
    Curhan GC, Goldfarb DS. Curhan GC, et al. Clin J Am Soc Nephrol. 2023 Dec 14;19(5):653-5. doi: 10.2215/CJN.0000000000000399. Online ahead of print. Clin J Am Soc Nephrol. 2023. PMID: 38099948 Free PMC article. No abstract available.
  • Kidney Stone Prevention.
    Peerapen P, Thongboonkerd V. Peerapen P, et al. Adv Nutr. 2023 May;14(3):555-569. doi: 10.1016/j.advnut.2023.03.002. Epub 2023 Mar 9. Adv Nutr. 2023. PMID: 36906146 Free PMC article. Review.

References

    1. Qaseem A, Dallas P, Forciea MA, et al.: Dietary and pharmacologic management to prevent recurrent nephrolithiasis in adults: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2014; 161: 659–67. - PubMed
    1. Hsi RS, Yan PL, Goldfarb DS, et al.: Comparison of Selective Versus Empiric Pharmacologic Preventative Therapy With Kidney Stone Recurrence. Urology 2020. - PMC - PubMed
    1. Samson PC, Holt SK, Hsi RS, et al.: The Association Between 24-Hour Urine and Stone Recurrence Among High Risk Kidney Stone Formers: A Population Level Assessment. Urology 2020; 144: 71–76. - PubMed
    1. Nicar MJ, Peterson R and Pak CY: Use of potassium citrate as potassium supplement during thiazide therapy of calcium nephrolithiasis. J Urol 1984; 131: 430–433. - PubMed
    1. Pak CY: Citrate and renal calculi: an update. Miner Electrolyte Metab 1994; 20: 371–377. - PubMed

Publication types